CAM2038

CAM2038 is a novel, extended-release injectable formulation of buprenorphine designed for the treatment of opioid use disorder and chronic pain. It is available as both weekly and monthly subcutaneous depot injections, enabling flexible dosing from initiation through long-term maintenance therapy. The drug utilizes Camurus’ FluidCrystal injection depot technology, which forms a gel matrix upon injection to provide sustained release of buprenorphine. Administration by healthcare professionals ensures adherence and reduces risks associated with diversion or misuse. Clinical trials have demonstrated that CAM2038 produces robust opioid blockade, suppresses withdrawal symptoms, and provides effective pain relief in opioid-experienced patients[1][2][3][4][5][6]. Its safety profile is consistent with known effects of buprenorphine.

Brand names

BuvidalBrixadi

Other names

Buvidal